Bath Savings Trust Co Sells 193 Shares of Novo Nordisk A/S (NYSE:NVO)

Bath Savings Trust Co trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 2.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,791 shares of the company’s stock after selling 193 shares during the quarter. Bath Savings Trust Co’s holdings in Novo Nordisk A/S were worth $541,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Nisa Investment Advisors LLC boosted its position in shares of Novo Nordisk A/S by 36.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,500 shares of the company’s stock worth $129,000 after purchasing an additional 400 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares in the last quarter. Mayflower Financial Advisors LLC boosted its position in shares of Novo Nordisk A/S by 13.3% in the 4th quarter. Mayflower Financial Advisors LLC now owns 7,613 shares of the company’s stock worth $655,000 after purchasing an additional 894 shares in the last quarter. SteelPeak Wealth LLC boosted its position in shares of Novo Nordisk A/S by 70.3% in the 4th quarter. SteelPeak Wealth LLC now owns 7,801 shares of the company’s stock worth $671,000 after purchasing an additional 3,220 shares in the last quarter. Finally, Hanson & Doremus Investment Management boosted its position in shares of Novo Nordisk A/S by 6,578.9% in the 4th quarter. Hanson & Doremus Investment Management now owns 5,076 shares of the company’s stock worth $437,000 after purchasing an additional 5,000 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $69.46 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market cap of $311.71 billion, a PE ratio of 21.11, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The firm has a fifty day simple moving average of $65.63 and a two-hundred day simple moving average of $82.01.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on NVO shares. Hsbc Global Res raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Wall Street Zen raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. Guggenheim cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.